Top Story Today
Bitter Taste Receptors in the Heart: Why Aardvark Just Killed Its Whole Obesity Pipeline
Aardvark Therapeutics voluntarily paused its entire obesity pipeline following a comprehensive review of the data, hammering investor confidence. The company's drug, ARD-101, works by activating bitter taste receptors in the gut to suppress hunger. Separately, cardiac safety observations emerged in the ARD-101 Phase 3 Prader-Willi syndrome trial at above-target doses, raising the possibility that the safety issue is baked into the mechanism itself, not just a dosing mistake. With approximately $122–127 million in estimated cash and no active trials, Aardvark now waits on FDA guidance expected in Q2 2026. In a market where Novo Nordisk and Eli Lilly are already launching oral alternatives, the margin for error is zero.
Why it matters: A full pipeline freeze in the white-hot obesity space is a stark reminder that clever biology can become a liability when your drug's target shows up in the wrong organ. With billions flowing into GLP-1 alternatives, investors have no reason to wait around for a cardiac question mark to resolve.
Read more →Supply Chain and Medtech
A War Just Disrupted Qatar's Ras Laffan Complex, and MRI Scanners Could Be Next
Iranian strikes on Qatar's Ras Laffan complex damaged LNG production and reduced export capacity by 17%, with potential knock-on effects for helium supply given the facility's role in global production. Spot prices have doubled since early March. Conventional MRI scanners worldwide that depend on liquid helium for cooling run on just-in-time refills, making hospitals among the first to feel any squeeze. Helium-free MRI technology exists but covers only a fraction of installed systems.
Read more →Clinical and Regulatory
Innovent's Eye Drug Matched Eylea on Vision Gains, Then One-Upped It on Dosing
In a Phase 3 trial, Innovent's efdamrofusp alfa matched Regeneron's blockbuster Eylea for wet AMD, with nearly 73% of patients stretching to once-every-16-week dosing. That handily beats Eylea's standard 8-week schedule. Innovent is targeting China approval first, where Eylea's grip is loosening.
Read more →Deals and Partnerships
GlycoNex and Nippon Kayaku Partner on a Cancer Drug That Plays Dead Until It Reaches the Tumor
The two companies are co-developing GNX201-ADC, an antibody-drug conjugate that wears a molecular mask in the bloodstream and only activates when tumor-specific enzymes strip it off. The preclinical-stage deal adds to a booming ADC market projected to hit $15 to $18 billion in 2026. Financial terms were not disclosed.
Read more →Merck Pays $20M Upfront for a Startup That Reads Your Cells' Natural Mutations
Quotient Therapeutics, a roughly four-year-old Flagship Pioneering spinout, landed a deal worth up to $2.2 billion to discover new IBD drug targets using its somatic genomics platform. The technology studies naturally occurring mutations in patient tissue to identify which genes drive disease. Quotient now counts Merck, Pfizer, and GSK as partners, though no named targets have been publicly disclosed yet.
Read more →